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article.journal homepage: www.elsevier .com/ locate / jva lEDITORIALUniversal Health Coverage—Big Thinking versus Big DataThese days we hear a lot about ‘‘big data’’ and how comparative
effectiveness research (CER) is going to help us make better
decisions (big data refers in the health care context to long-
itudinal medical claims data for millions of patients linked to
their electronic health records [1]). Most of us working in
pharmacoeconomics and outcomes research rely on data—both
randomized and observational—to generate and assess evidence
with the aim of supporting better decision making about resource
allocation. Most articles in Value in Health are research or methodol-
ogy articles: the number of policy articles is very limited. My quick
search for ‘‘universal health coverage’’ (UHC) found only 11 citations
in the journal, but none focusing on UHC. The articles in this special
supplement, based on a conference held at Bocconi University in
Milan, Italy, earlier this year, remind us that there are large and
important policy issues that rely on ‘‘big thinking’’—with less hard
evidence—to understand and try to reform what is going on in
health systems and health policy. Nonetheless, as we often empha-
size to others, decisions will have to be made—with or without good
information—and making no decision is itself a choice.
The eight articles in this special issue illustrate the diversity
of the approaches and methods that social scientists use to
understand and meet the evolving challenges of an increasingly
complex and global health care environment. Economics and
other social sciences can help us to think big about incentives
and likely behavioral responses in an important qualitative
fashion even if quantitative rigor is infeasible. This conference
and these articles were mostly about big thinking based on a
limited number of—what economists like to call—‘‘stylized
facts,’’ that is, generally held propositions about behavior, often
based on a broad review of the state of our knowledge.
To be clear, big data in the form of CER may be well worth
subsidizing and even requiring through regulation because infor-
mation generally has public good properties, and we expect it to
be undersupplied in a competitive marketplace—a big thinking
result itself. However, big thinking alone will not tell us the
optimal amount of CER: we need empirical evidence on the
impact of having more information. But we also know that more
information is neither necessary nor sufficient for better decision
making: arguably, the major developed countries have to work
with the same limited evidence on what works well in medicine,
yet some achieve much better population-level health outcomes.
But big thinking or theory may not be sufficient either: for
example, economics cannot, of course, tell us a priori whether
one medicine is clinically better than another, but it can suggest
how we could encourage the use of a better medicine by using
incentives.
Our field seems polarized at times between those who want to
rely primarily on randomized, controlled clinical trials and thoserest: The author has indicated that there is no cwho want to use primarily real-world, observational data (though
they are most happy to have natural experiments). And then
there are the modelers in between the groups who are busy
trying to synthesize the data from both sources. The decision in
the United States about whether to subsidize CER and fund the
Patient-Centered Outcomes Research Institute was more of a big
thinking result. There is, however, a certain irony in the fact that
the Congressional Budget Office produced estimates of the
potential aggregate, longer-term impact of CER based on a model
(with obviously very limited, directly relevant data) [2].
This special issue is about the many facets and issues that
surround the widely sought goal of UHC. The World Health
Organization (WHO) defines it this way:
Universal coverage is defined as access to key promotive,
preventive, curative and rehabilitative health interventions for
all at an affordable cost, thereby achieving equity in access.
The principle of financial-risk protection ensures that the cost
of care does not put people at risk of financial catastrophe. A
related objective of health-financing policy is equity in finan-
cing: households contribute to the health system on the basis
of ability to pay. Universal coverage is consistent with WHO’s
concepts of Health for All and Primary Health Care.
This topic is very timely and was also the subject of a series of
recent articles in The Lancet; see, for example, the accompanying
journal editorial [3].
I imagine that the large majority of ISPOR members would
subscribe to this as a worthy goal for a national health care
system. But most of the research that we do takes the overall
health care system as given and aims to improve resource
allocation given a limited budget or resources. Our widely used
method of cost-utility analysis based on the quality-adjusted life-
year (QALY) does not include a factor for ‘‘financial risk protec-
tion.’’ Nonetheless, the peace of mind that comes from having
protection against catastrophic financial loss from poor health is
of great value and importance to most of us, and most developed
countries have adopted UHC. For example, this is part of the
welfare loss that the millions of uninsured in the United States
suffer from not having health insurance. To my knowledge, no
one has tried to calculate this part of the welfare loss in the
aggregate, and in comparison to the direct health and well-being
loss due to reduced utilization because of poor access, which is
also very important and large.
Without attempting a thorough synopsis of each article in this
issue, in the next few paragraphs, I will highlight what were—for
me—some of the most interesting findings and observations in
the eight articles, with the aim of providing a quick sense of theonflicts of interest to disclose with regard to the content of this
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to the crosscutting theme of UHC.
The conference and this issue were motivated by Tarricone in
a big thinking article that asserts that UHC is the major issue in
international health and challenges us to think about three major
trends that will affect the ability of societies to achieve it:
accelerating technological change, the aging of populations, and
the epidemiological transition to chronic disease—even in less
developed countries. She sees the current era of accelerating
change as one in which revolutionary ideas are needed and are
best generated through advancing education. Her major point is
that given these challenges, ‘‘y education needs to foster
imagination and creativity.’’ In its 13 years of existence, the
Masters in International Healthcare Management, Economics
and Policy at Bocconi has graduated more than 400 students
from more than 70 countries. She believes that this kind of
diversity in education worldwide will be the driver of the changes
that are needed. She concludes with a call to arms for all of us to
help to drive this change.
The team of McKee, Balabnova, Balabanova, Basu, Ricciardi,
and Stuckler combines previous data analysis with big thinking
about historical factors to review the potential fragility of UHC.
The optimists among us tend to assume that change is generally
evolutionary and is a good thing (i.e., changes are tested in the
real world and good ones survive). In the US context, the repeal of
Secretary Bowen’s Catastrophic Insurance Act in the late 1980s [4]
and efforts to repeal the current Affordable Care Act would be
enough to convince most that greater insurance protection is not
irreversible. A prior study [5] defined UHC operationally as being
‘‘y in place where there was legislation explicitly stating that the
entire population is covered by a defined health plan and where
that population has access to at least skilled attendance at birth
and 90% of them have insurance coverage.’’ By this criterion, they
found that 58 of 194 countries had UHC, and surprisingly several
of them were relatively poor. For example, the United Kingdom
achieved this in 1948 and both Thailand and Rwanda very
recently. They point out that there are numerous theoretical
frameworks (e.g., class or development theories) that can be used
to understand these developments, but none alone provides a
satisfactory explanation. They sift through the data to identify
five key factors that enable UHC: ‘‘the strength of organized labor
and those left-leaning parties that represent them, the availabil-
ity of resources (including economic growth), potential for build-
ing shared identities and public goals (as seen in more
homogenous societies), path dependency (so that the conditions
today impact the possibilities for tomorrow), and windows of
opportunity (often created by exogenous events such as financial
crises, natural disasters or wars, or political transitions).’’ Clearly,
this is big thinking and is quite plausible and understandable, but
it will be difficult to undertake any definitive measurement of
these factors and their quantitative relationship. The authors
conclude with the caution that history has shown that reforms
are reversible and that windows of opportunity, such as the Great
Recession of 2008, might also provide an opening for the oppo-
nents of UHC to undo it.
The article by Missoni is another good example of big
thinking—an analytical policy piece (‘‘a systems thinking
approach’’) that explores the potential impact of global trade
liberalization on UHC. The article systematically assesses the
possible adverse impacts of global trade on each of WHO’s six
health system building blocks: service delivery; health workforce;
information; medical products, vaccine, and technologies; finan-
cing; and leadership and governance. While trade and knowledge
spillovers—for example, the availability of low-cost, first-line
antiretroviral treatment for HIV disease—can benefit those in
developing countries, the article identifies numerous possible
adverse effects. These range from the ‘‘commercialization’’ ofhealth care under trade agreements, to the disconnect between
drug development and the global burden of disease, to the
exportation of unhealthy Western lifestyles and habits, to numer-
ous other examples. This is a big thought experiment in need of
some systematic quantification and evidence development.
Nonetheless, this long list challenges us to entertain the possi-
bility that further global regulation and coordination is needed if
UHC is going to succeed in more nations. This may be another
case where uncertainty produces a type of market failure that
justifies a regulatory intervention. Missoni argues for strengthen-
ing the role of the WHO in promoting ‘‘global governance for
health’’ in our increasingly connected world.
The article by Fattore and Tadiosi on cultural values and their
role in governance in relation to UHC is another good example of
a big conceptual thought piece. They lay out a plausible story of
how different underlying cultural values can lead societies to
select different management and governance structures that are
more or less friendly to UHC. They distinguish between ‘‘manage-
ment’’ and ‘‘governance,’’ the former being more about opera-
tional activities and the latter about how policies and regulations
are developed and monitored. They emphasize, however, that not
only are both management and governance critical to supporting
UHC policies, but these solutions and how they are developed are
related to underlying cultural values. Interestingly, on the basis of
cultural theory, they characterize four cultural archetypes: hier-
archist, individualist, fatalist, and egalitarian. These archetypes
vary—oversimplifying a good bit—depending on two dimensions
in a society: the importance of rules and authority structures,
and the group versus individual orientation. Interestingly, they
weave a complex story, arguing that it is not clear that any one
archetype is most conducive to UHC. The hierarchist and egali-
tarian perspectives both share a ‘‘groupness’’ orientation that
should be enabling to some degree. On the other hand, they do
not rule out an individualist solution to providing UHC. This is
another example of big, complex thinking that may yield some
testable implications if we can begin to measure the archetypes.
Their major conclusion, however, is more subtle: implementation
can matter as much as the goals implied by cultural values. In
other words, both management and governance are important
for the implementation and sustainability of UHC, and how they
are best used to support a UHC goal will depend on societal
cultural values.
The article by Lega, Prenestini, and Spurgeon is more empiri-
cally grounded than some of the preceding thought pieces but
complements them by summarizing the evidence on the impor-
tance of management practices. They point out that both public
and private health systems are struggling with cost
containment—and therefore with the broader issue of sustain-
ability: thus, the management of these health plans comes into
question. They attempt to summarize a large and complex
literature, consisting of both qualitative and quantitative studies,
on this topic. They conclude that yes, management matters. And
they note the intriguing finding that health care managers with
some clinical background seem to do a better job. This is not
necessarily surprising, but it does imply that training managers
to have both clinical and business skills means a larger societal
investment. Others in this special issue emphasize the impor-
tance of management and particularly in relation to the need for
proper health system governance at both a health plan level and
a supranational level if UHC is to be promoted and succeed in our
rapidly changing world.
The article by Villa and Kane is the only one in this issue that
proffers a new empirical analysis. They identify all hospital
conversions (from public to private, for-profit) in three American
states (California, Florida, and Massachusetts) between 1994 and
2003. They find 58 conversions to analyze and compare them pre-
versus postconversion and in relation to a larger universe of
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ciated with reduced length of stay, costs, and the use of low-
margin services; also, prices and operating margins increased,
but access to community-based services in these hospitals
declined. They are understandably cautious in generalizing to
all conversions or to other countries. But it is clear that hospital
behavior and performance changes with changed incentives and
that there are trade-offs between access and cost. Pluralistic
health care systems attempting to achieve UHC by altering the
mixture of public and private hospitals will need to pay careful
attention to this trade-off. In the United States, the use of the
emergency room as the safety-net provider of last resort has been
a costly and imperfect way of providing UHC because it most
likely fails to provide the important peace of mind that is a key
aim of UHC.
The article by Drummond, Tarricone, and Torbica addresses
the challenges that UHC systems face in trying to provide access
to costly innovative technologies. Of all the articles in this issue,
it probably falls more into the comfort zone of Value in Health
readers in terms of terminology and concepts, while still provid-
ing some new insights into the relationship between health
technology assessment (HTA) and UHC. They note the natural
tension that exists among the key stakeholders—patients,
payers, and manufacturers of innovative technologies. Patients
want (via their physician agents) access to new technologies that
provide positive net clinical benefit; payers need to manage their
budget and want value for the money spent on behalf of their
clients—the taxpayers or plan members; and manufacturers seek
rewards that would provide the best return on their substantial
investments. They ask: how can we reconcile the conflicting
interests among these stakeholders? They note that some
systems—most notably the National Institute for Health and
Clinical Excellence (NICE) in the United Kingdom—have used an
HTA evaluation system based on the QALY to make judgments
about value and access recommendations regarding specific tech-
nologies. They cite the well-known limitations of the QALY and
NICE’s pragmatic adjustments to deal with them. I would only
repeat that the QALY as usually implemented does not reflect the
peace-of-mind premium that is one key aim of UHC. They argue
that the QALY may not adequately reflect ‘‘social value’’—a broader
concept that would consider more products attributes than just the
incremental cost-effectiveness ratio. They also identify other ana-
lytic options—such as discrete choice experiments—that could
weigh other criteria as well. The authors also note the limitations
of the current drug development paradigm (e.g., placebo-controlled
randomized clinical trials and noninferiority randomized clinical
trials in highly selected populations). Earlier dialogue with payers is
suggested as a useful approach to address this. The greater
emphasis on CER is noted. Finally, they cover at length the
challenges of promoting greater patient involvement in HTA deci-
sion making, which HTA practitioners have recognized and been
promoting since the 1990s. They would clearly support the idea of
producing big data to enable CER and better HTA decision making,
and they make specific recommendations for specific studies and
methods experiments to support policy choices. This article is
another good example of the need for and power of big (analytical)
thinking to sort out critical issues and to define a research and
policy agenda.In the final article in this issue, Borgonovi and Compagni
return us to the question of the sustainability of UHC that was
also raised in the McKee et al. article. UHC is currently an
aspiration not only in emerging markets such as Brazil, China,
and India but also in the United States. They emphasize that
when most analysts think about sustainability, they are mostly
thinking about economic sustainability. It is important to
acknowledge, however, that sustainability has political and social
dimensions as well. Like the McKee et al. article, the policy
analysis and commentary in this article suggests that the
economic unsustainability might be used as an argument to
undermine social and political sustainability. In the realm of
assessing economic sustainability, they argue persuasively that
there is a greater role for the analysis of management practices.
There is not space here for me to fully explore subtle and useful
distinctions that they make in defining social and political
sustainability. I was intrigued, however, by their observation that
UHC could ‘‘y generate positive social spillovers (or social value)
well beyond health’’ that would contribute to social and political
sustainability. Again, the article argues both conceptually and
using country case examples: another example of big thinking
using the limited data available.
The preceding overviews will, hopefully, help readers of this
issue identify where they would like to dig more deeply. To end by
reiterating two major contentions: 1) big data can clearly support
better decision making, but understanding and altering incen-
tives is probably more important for producing population health
improvements, and 2) in the end, many major policy decisions
are based on limited data and are driven more by big thinking
about incentives and likely responses—and by politics. The big
thinking in this special issue stimulates us to broaden our view of
how we can grapple with the challenge of pursuing UHC.
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